Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L J Schaaf

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patientsJ G Slatter, L J Schaaf, J P Sams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Clinical Pharmacology and Therapeutics|May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analysesM A Phelps, T E Stinchcombe, J S Blachly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patientsJ G Slatter, L J Schaaf, J P Sams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Clinical Pharmacology and Therapeutics|May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analysesM A Phelps, T E Stinchcombe, J S Blachly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Pageof 3